Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16889
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBjörnmal, Mattias-
dc.contributor.authorThurecht, Kristofer J-
dc.contributor.authorMichael, Michael-
dc.contributor.authorScott, Andrew M-
dc.contributor.authorCaruso, Frank-
dc.date2017-09-19-
dc.date.accessioned2017-10-03T05:32:15Z-
dc.date.available2017-10-03T05:32:15Z-
dc.date.issued2017-09-19-
dc.identifier.citationACS Nano 2017; 11(10): 9594-9613en_US
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/16889-
dc.description.abstractThe interface of bio-nano science and cancer medicine is an area experiencing much progress but also beset with controversy. Core concepts of the field-e.g., the enhanced permeability and retention (EPR) effect, tumor targeting and accumulation, and even the purpose of "nano" in cancer medicine-are hotly debated. In parallel, considerable advances in neighboring fields are occurring rapidly, including the recent progress of "immuno-oncology" and the fundamental impact it is having on our understanding and the clinical treatment of the group of diseases collectively known as cancer. Herein, we (i) revisit how cancer is commonly treated in the clinic and how this relates to nanomedicine; (ii) examine the ongoing debate on the relevance of the EPR effect and tumor targeting; (iii) highlight ways to improve the next-generation of nanomedicines; and (iv) discuss the emerging concept of working with (and not against) biology. While discussing these controversies, challenges, emerging concepts, and opportunities, we explore new directions for the field of cancer nanomedicine.en_US
dc.subjectAntibodiesen_US
dc.subjectComparative oncologyen_US
dc.subjectHeterogeneityen_US
dc.subjectMetastasisen_US
dc.subjectNanoengineeringen_US
dc.subjectNanomaterialsen_US
dc.subjectNanoparticlesen_US
dc.subjectTumor targetingen_US
dc.titleBridging bio-nano science and cancer nanomedicineen_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleACS Nanoen_US
dc.identifier.affiliationDepartment of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationARC Centre of Excellence in Convergent Bio-Nano Science and Technology, and the Department of Chemical and Biomolecular Engineering, The University of Melbourne , Parkville, Victoria, Australiaen_US
dc.identifier.affiliationARC Centre of Excellence in Convergent Bio-Nano Science and Technology, The Australian Institute for Bioengineering and Nanotechnology and The Centre for Advanced Imaging, The University of Queensland , Brisbane, Queensland, Australiaen_US
dc.identifier.affiliationDivision of Cancer Medicine, Peter MacCallum Cancer Centre , Melbourne, Victoria, Australiaen_US
dc.identifier.affiliationThe Peter MacCallum Department of Oncology, The University of Melbourne , Parkville, Victoria, Australiaen_US
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, and School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australiaen_US
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/28926225en_US
dc.identifier.doi10.1021/acsnano.7b04855en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0002-4100-3131en
dc.identifier.orcid0000-0002-6656-295Xen
dc.identifier.orcid0000-0002-0197-497Xen
dc.identifier.orcid0000-0002-9876-7079en
dc.type.austinJournal Articleen_US
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.